

23 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/23/3242470/0/en/C4-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-MOMENTUM-Trial-of-Cemsidomide-an-Oral-IKZF1-3-Degrader-in-Combination-with-Dexamethasone-for-Relapsed-Refractory-Multiple-M.html

14 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/14/3218491/0/en/C4-Therapeutics-Outlines-Strategic-Milestones-to-Advance-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-and-Discovery-Strategy-Focused-on-Novel-Targets-in-Clinically-Val.html